Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers

Phase 1

Completed

• Conditions: Advanced Cancer
• Interventions: Drug: Chlorogenic acid

• Registration Number: NCT02245204
• Lead Sponsor: Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd

Brief Summary

The purpose of this study:

Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced malignant tumor subjects;

Detailed Description

1. Investigate the tolerance of Chlorogenic acid for injection in human body, determine the Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT) of Chlorogenic acid for injection in the advanced malignant tumor subjects;

2. Determine the human pharmacokinetics characteristic of Chlorogenic acid for injection;

3. Preliminary observation the effectiveness and effective dose;

4. Provide the basis for the dosage regimen of phase II/III.

Study Timeline

• Study Start: 2014-09
• Study First Submitted: 2014-09-16
• Study First Submitted QC: 2014-09-16
• Study First Posted: 2014-09-19
• Primary Completion: 2016-10
• Study Completion: 2016-10
• Status Verified: 2018-10
• Last Update Submitted: 2018-11-19
• Last Update Posted: 2018-11-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. Patients with pathologic or/and FNAC confirmation of advanced cancer but without effective treatment or with treatment failure;

2. Between 18 and 65 years of age, KPS≥70;

3. According to RECIST 1.1,patients with at least one tumor lesion that can accurately be measured by CT or MRI in at least one dimension with longest diameter to be recorded as >2.0cm by general CT or >1.0cm by spiral CT;

4. Life expectancy of at least three (3) months at the enrollment;

5. Patients who have sufficient baseline organ function and whose laboratory data can meet the following criteria at the enrollment:

   • PLT count≥100×10~9/L,
   • WLB count≥4.0×10~9/L and ≤12×10~9/L,
   • Neutrophil granulocyte count≥2.0×10~9/L,
   • HGB count≥90g/L,
   • Total bilirubin <=1.5 times of ULN,
   • ALT/AST ≤2.5 times of ULN,
   • SCr≤1.5 times of ULN,
   • Normal ECG with LVEF (≥50%) measured by echocardiography;

6. Female patients with negative pregnant test, and male/female patients of reproductive age without pregnancy planning in the next 12 months;

7. Volunteered for the phase 1 trial and sign the informed consent without protest;

Exclusion Criteria

1. Patients who have received large area radiotherapy （>30% marrow capacity）;
2. Patients who suffer from other serious complication, such as uncontrollable infection, myocardial infarction within the past 6 months at the enrollment , uncontrollable hypertension ,thromboembolism and etc.;
3. Symptomatic patients with brain metastases (except for the patients whose brain metastases is controlled to stable status after whole brain radiotherapy);
4. Patients who have received the therapy of chemotherapy within 4 weeks before enrollment;
5. Patients who have used nitrosoureas drug or mitomycin within 6 weeks or tyrosine kinase inhibitor within 2 weeks before enrollment;
6. Patients who have received therapy of major surgery within 6 weeks or biopsy surgery within 2 weeks before enrollment;
7. Patients who or have received radical radiotherapy within 6 weeks or local palliative radiotherapy within 2 weeks before enrollment;
8. Patients who experience grade 2 or more than grade 2 toxicity caused by the past therapies;
9. Patients who have history of drug abuse or alcoholism;
10. Patients who smoke over 5 cigarettes or equivalent tobacco per day;
11. Uncontrollable psychopaths;
12. Pregnant or breast-feeding women, or patients(male and female) who have pregnancy plan;
13. Patients who had received a therapy of another investigational drug within 4 weeks or patients who are still in another clinical trial at the enrollment;
14. Known active hepatitis B/hepatitis C, positive HIV/ syphilis antibody;
15. Patient who need long term treatment of cortical hormone or other immunosuppressive drugs such as visceral organ transplanters;
16. Allergic to the investigational drug;
17. Other patients judged ineligible for enrollment in the study by the investigator (sub-investigator).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Chlorgenic acid, Treatment, powder	Chlorogenic acid	Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.

Primary Outcome Measures

Name	Time	Method
Number of adverse events	Within the first 60 days after the first dose of chlorogenic acid

Secondary Outcome Measures

Name	Time	Method
Dose-Limiting Toxicity	Within the first 30 days after the first dose of chlorogenic acid
Maximum Tolerated Dose	Within the first 30 days after the first dose of chlorogenic acid
Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of chlorogenic acid	Within the first 30 days after the first dose of chlorogenic acid
Improvement in cancer-related symptoms and quality of life	Within 1 year after the first dose of chlorogenic acid

Trial Locations

Locations (1)

Beijing Cancer Hospital; 🇨🇳 Beijing, China